Va-Va-Voom? Not So Fast, Says the TTAB
Key Takeaways: Descriptive additions to composite trademarks, especially those disclaimed by the applicant, will rarely overcome a Section 2(d) likelihood of confusion where the dominant term is identical. Critically, arguments...
FDA to Hold Public Meeting on Proposed Medical Device Review Recommendations
Key Takeaway: The FDA announced a public meeting and request for comments on proposed Medical Device User Fee Amendments (MDUFA )recommendations for fiscal years 2028-2032, which would govern medical device...
Solar Surpasses Coal in the U.S. For the First Time
Key Takeaway: Solar has reached a historic milestone, surpassing coal in U.S. electricity generation as rising demand and record investment accelerate the transition to renewable energy. As innovation and competition...
Not All Mifflins Are Equal: When Commercial Impression Saves the Day
Key Takeaway: Even where goods are identical or closely related, the TTAB continues to place significant weight on differences in commercial impression. A mark’s meaning, whether driven by pop culture...
Federal Circuit Review | June 2026
When ‘Any Patent’ Means No Patent: Federal Circuit Reverses Non-Specific Verdict In Ollnova Technologies Ltd. v. Ecobee Technologies ULC [Opinion], Appeal No. 25-1045, the Federal Circuit held that a...
Supersonic Flight Could Return to the U.S. Soon: FAA Proposes Framework for Commercial Supersonic Flight
Key Takeaway: The FAA’s proposed performance-based framework could create a path for routine commercial supersonic flight over land in the U.S. Aerospace companies developing supersonic aircraft, boom-mitigation systems, and compliance...
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient With “A Unit Dosage” in Wyeth LLC v. Astrazeneca Pharmaceuticals LP.
Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal growth factor receptor...
OBBBA’s Construction Deadline Has Passed – Now the Continuity Risk Begins
Key Takeaways: The One Big Beautiful Bill Act (OBBBA) accelerated development timelines across the renewable energy sector by creating a limited window for developers to preserve valuable federal tax incentives....
When “About” Becomes Indefinite: Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v. Safe Foods
Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance, “about” may...
